AbCellera’s technology tackles the biggest challenges limiting antibody discovery for transmembrane proteins. Watch this video to find out more.
GPCRs and ion channels are highly sought-after drug targets, but of the ~300 well-validated opportunities, only two antibody drugs have been approved.
AbCellera’s technology tackles the biggest challenges limiting antibody discovery for transmembrane proteins: producing antigens, driving antibody responses, and finding hits.
Optimized immunization strategies, single-cell screening technologies, and hyper-scale data science leads to hundreds of hits, and by integrating Tetrahymena — a natural membrane protein factory — we’re driving powerful solutions to unlock these targets.
